TrialThe New England journal of medicine2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,806 papers cite itlatest 60 shown
this paperpooled ittrialcites it